How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

GLP-1 vs. non-GLP-1 anti-obesity medications: Differences in patient profiles

calendar_today November 9, 2026 person Truveta staff domain truveta

Authors: Claire Campbell, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Sarah Eng, MPH ⊕, Truveta, Inc, Bellevue, WA, USA Jeffrey Ratto, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Katie Gilbert, MPH ⊕, Truveta, Inc, Bellevue, WA, USA Amy Austin, MHI ⊕, Truveta, Inc, Bellevue, WA, USA Ekaterina Khlystova, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Sunny Guin, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Vidya Venkataraman, MPH, PhD ⊕ Truveta, Inc, Bellevue, WA, USA Compared with adults who started a non-GLP-1 anti-obesity medication, GLP-1 initiators were older, less likely to be female, and had more cardiometaboli

open_in_new Read original post